| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
49,810 |
46,207 |
$3.55M |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
14,887 |
14,350 |
$1.53M |
| 99393 |
Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) |
7,085 |
7,081 |
$653K |
| 99392 |
Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) |
6,200 |
6,198 |
$570K |
| 90460 |
Immunization administration through 18 years of age via any route, first or only component |
21,470 |
21,422 |
$525K |
| 99394 |
Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) |
3,079 |
3,079 |
$308K |
| 99391 |
Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) |
3,489 |
3,474 |
$299K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
2,883 |
2,832 |
$130K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
7,402 |
3,639 |
$110K |
| 87502 |
Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets |
824 |
805 |
$66K |
| 87651 |
Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe |
2,027 |
1,987 |
$60K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
931 |
913 |
$46K |
| 90471 |
Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine |
2,184 |
2,181 |
$25K |
| 87081 |
|
2,705 |
2,664 |
$18K |
| 96127 |
|
3,607 |
3,606 |
$15K |
| 17110 |
|
135 |
91 |
$15K |
| G2023 |
Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source |
2,898 |
2,857 |
$11K |
| 99215 |
Prolong outpt/office vis |
26 |
26 |
$4K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
345 |
340 |
$4K |
| 83655 |
|
363 |
362 |
$4K |
| G8510 |
Screening for depression is documented as negative, a follow-up plan is not required |
1,724 |
1,724 |
$3K |
| 85018 |
|
969 |
967 |
$2K |
| 80061 |
Lipid panel |
125 |
125 |
$2K |
| 90461 |
|
30 |
30 |
$1K |
| 99381 |
|
14 |
14 |
$1K |
| 87634 |
|
16 |
16 |
$1K |
| 81002 |
|
315 |
308 |
$981.93 |
| 82947 |
|
186 |
186 |
$671.60 |
| 96110 |
Developmental screening, with scoring and documentation, per standardized instrument |
176 |
176 |
$438.68 |
| 0071A |
|
16 |
16 |
$400.00 |
| 0072A |
|
15 |
15 |
$375.00 |
| 99050 |
|
36 |
36 |
$319.86 |
| 99000 |
|
2,250 |
2,194 |
$241.80 |
| 90473 |
|
34 |
34 |
$230.00 |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
15 |
14 |
$207.32 |
| 94760 |
|
1,333 |
1,294 |
$86.83 |
| A7003 |
Administration set, with small volume nonfiltered pneumatic nebulizer, disposable |
15 |
14 |
$36.42 |
| 99174 |
|
2,388 |
2,388 |
$20.91 |
| A7015 |
Aerosol mask, used with dme nebulizer |
15 |
14 |
$15.00 |
| 90686 |
|
7,362 |
7,361 |
$0.00 |
| 90656 |
|
517 |
517 |
$0.00 |
| 90647 |
|
887 |
887 |
$0.00 |
| 90723 |
|
924 |
924 |
$0.00 |
| 90677 |
|
64 |
64 |
$0.00 |
| 90651 |
|
262 |
262 |
$0.00 |
| 90660 |
|
16 |
16 |
$0.00 |
| 1036F |
|
36 |
36 |
$0.00 |
| 90696 |
|
39 |
39 |
$0.00 |
| 91307 |
|
28 |
28 |
$0.00 |
| 90670 |
|
1,945 |
1,945 |
$0.00 |
| 90633 |
|
266 |
266 |
$0.00 |
| 90734 |
|
394 |
394 |
$0.00 |
| 90681 |
|
135 |
135 |
$0.00 |
| 90715 |
|
79 |
79 |
$0.00 |
| 90671 |
|
254 |
254 |
$0.00 |
| 90672 |
|
98 |
98 |
$0.00 |
| 90710 |
|
38 |
38 |
$0.00 |
| G8431 |
Screening for depression is documented as being positive and a follow-up plan is documented |
12 |
12 |
$0.00 |